GSK
GSK confirms deal to supply 300 million COVID-19 vaccine doses to the EU
September 25, 2020Manufacturing and Production, Medical Communications COVID-19, EU, GSK, Vaccine
GlaxoSmithKline has confirmed a new COVID-19 vaccine supply deal to deliver 300 million doses of its candidate to the European …
President of Sanofi France expects COVID-19 vaccine to be priced below ten Euros
September 7, 2020Sales and Marketing COVID-19, GSK, Sanofi
The President of Sanofi France expects the coronavirus vaccine it is developing with GlaxoSmithKline to be priced under 10 Euros. …
US Government commits $2.1bn to GSK and Sanofi’s COVID-19 vaccine candidate
July 31, 2020Medical Communications, Research and Development COVID-19, GSK, Sanofi, US, Vaccine
The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the …
UK Government secures 60 million doses of Sanofi and GSK’s COVID-19 vaccine
July 29, 2020Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK government, pharma
The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi …
FDA committee backs GSK’s belantamab mafodotin in relapsed or refractory multiple myeloma
July 15, 2020Research and Development, Sales and Marketing Cancer, FDA, GSK, multiple myeloma, pharma
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has moved to recommend the use of GlaxoSmithKline’s belantamab mafodotin, or GSK2857916 as …
Ex-GSK exec named as Chief Medical Officer at Immatics Biotechnologies
June 10, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, appointment, immatics
Immatics Biotechnologies welcomed former GlaxoSmithKline executive Dr Cedrik Britten to the company as its new Chief Medical Officer (CMO) on …
GlaxoSmithKline commits to the production of one billion doses of COVID-19 vaccine adjuvant in 2021
May 28, 2020Manufacturing and Production COVID-19, GSK, coronavirus, pharma, vaccines
GlaxoSmithKline has just come forward to commit to the manufacture and distribution of one billion doses of vaccine adjuvant against …
Evox appoints ex-GSK exec Martin Andrews as new non-Executive Director
May 28, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Evox, GSK, appointment
Evox Therapeutics has named ex-GlaxoSmithKline executive Martin Andrews as its new non-Executive Director, it has emerged. Andrews has previously …
Cleaning staff excluded from GSK’s £1.5k COVID-19 employee bonus
May 26, 2020Manufacturing and Production COVID-19, GSK, coronavirus, pharma
UK pharma giant GlaxoSmithKline has pledged to pay a cash bonus of £1,500 to staff continuing to work during the …
Sanofi and GSK set aside rivalry with “unprecedented” COVID-19 vaccine partnership
April 15, 2020Research and Development COVID-19, GSK, Sanofi, coronavirus
Usual rivals Sanofi and GlaxoSmithKline have said they are to put aside competition with the forging of a new “unprecedented …
Clover Biopharmaceuticals partners up with GSK to accelerate coronavirus vaccine development
February 24, 2020Sales and Marketing China, Clover Biopharmaceuticals, GSK, coronavirus, pharma
Chinese biotech firm Clover Biopharmaceuticals has joined the race to develop interventions against the ongoing coronavirus outbreak with the announcement …
GSK to axe 720 positions at Belgian vaccine facility
February 7, 2020Manufacturing and Production, Medical Communications GSK, job cuts, pharma
GlaxoSmithKline has announced a cull of staff at its vaccine production site in Belgium, with 720 employees facing the axe. …
FDA fast-tracks GSK’s multiple myeloma drug after priority review
January 22, 2020Research and Development BCMA, FDA, GSK, Phase 2 Trials, Phase Trials, multiple myeloma, myeloma
The FDA has fast tracked GlaxoSmithKline (GSK) antibody drug conjugate (ADC) belantamab mafodotin, for the treatment of patients with refractory …
GSK’s Nucala meets Phase 3 goal in reducing hypereosinophilic syndrome flare-ups
November 13, 2019Research and Development GSK, Nucala, pharma
GlaxoSmithKline has unveiled new Phase 3 data for its IL-5 inhibitor Nucala (mepolizumab), revealing that the therapy met its primary …
Expanded EU label for Benlyta now covers paediatric lupus patients
October 30, 2019Research and Development, Sales and Marketing Benlyta, Europe, GSK, Lupus, pharma
GlaxoSmithKline is celebrating the news that the European Commission has chosen to approve an expansion to the label of its …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
